Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa.

Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria.

Abstract: The subject invention encompasses methods for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria comprising administering bismuth to the subject.

Abstract: Disclosed are oral compositions such as toothpastes, mouthrinses, liquid dentifrices, lozenges and gums containing copper bis-glycinate.

Abstract: The present invention relates to oral and edible compositions intended to provide an anticaries benefit. The primary active ingredient in these compositions is a protein selected from the group consisting of cystatin S, cystatin SA, cystatin SN and mixtures thereof which are salivary proteins. Also included are fragments of the proteins which may be used in place of the total proteins.

Abstract: The present invention relates to improved topical pharmaceutical compositions having improved aesthetics which are useful for imparting antimicrobial actives. In particular, it relates to topical moisturizing compositions containing one or more antimicrobial active compounds. These compositions are also useful for providing relief from symptoms associated with, for example, vaginal yeast infections.

Abstract: The present invention relates to improved topical pharmaceutical compositions in the form of a wipe or towelette having improved aesthetics which are useful for imparting antimicrobial actives. In particular, it relates to topical moisturizing wipe compositions containing one or more antimicrobial active compounds. These compositions are also useful for providing relief from symptoms associated with, for example, vaginal yeast infections.

Abstract: The present invention relates to a mouthrinse and methods of use providing improved antimicrobial activity and thereby reducing oral bacteria, mouth malodor and further promoting oral health.

Abstract: The present invention relates to a mouthrinse and methods of use providing improved antimicrobial activity and thereby reducing oral bacteria, mouth malodor and further promoting oral health.

Abstract: The subject invention encompasses a denture adhesive composition comprising one or more adhesive components suitable for adhering to the oral cavity and a denture base and at least one non-adhesive self-supporting layer wherein the self-supporting layer is selected from the group consisting of polyester, polypropylene, nylon, rayon, polyethylene oxide, cellulose acetate, cellulose derivatives, cloth, paper, microcrystalline wax, synthetic fibers, natural fibers, and mixtures thereof.

Abstract: Disclosed are methods for treatment of herpes virus infections in a human or lower animal subject comprising administering to the subject stannous salt and one or more pharmaceutically acceptable carriers suitable for topical administration. The stannous salt may be one or more stannous carboxylates, a stannous halide selected from the groups consisting of stannous bromide, stannous iodide, and stannous chloride dihydrate, two or more stannous halides, or one or more stannous halides and one or more stannous carboxylates. Another therapeutic agent, such as an anesthetic, analgesic, or antibiotic, may also be administered. Also disclosed are compositions effective in treating herpes virus infections in a human or lower animal subject comprising stannous fluoride, one or more therapeutic agents, and one or more pharmaceutically acceptable carriers suitable for topical administration.

Abstract: Oral compositions, such as oral gels and toothpastes, containing a novel abrasive.

Abstract: The present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like, allergy, sinus and/or flu symptoms by administering a safe and effective amount of a composition comprising caffeine and certain pyrrolidine and piperidine ether antihistaminic agents.

Abstract: The present invention relates to improved pharmaceutical compositions containing an analgesic encapsulated within a soft gelatin shell wherein said shell contains a xanthine derivative, such as caffeine.

Abstract: Disclosed are oral compositions such as toothpastes, mouthrinses, liquid dentifrices, lozenges and gums containing at least one phosphate derivative and a copper source.

Abstract: The present invention provides novel methods for prevention or treatment of primary and recurring squamous cell carcinoma of the oral cavity or oropharynx comprising topical administration, to the oral cavity or oropharynx, of an effective amount of an NSAID, especially a composition administering from about 0.001% to about 0.2% ketorolac to the oral cavity, alone or as an adjunct to surgery and/or radiation therapy.

Abstract: Disclosed are drink mix compositions comprising a therapeutically effective dose of an anion exchange resin, xanthan gum, and an edible, water soluble salt at a level wherein the gelation rate of the drink mix compositions in a aqueous solution is reduced. These compositions may also contain one or more carriers wherein the compositions are in a form mixable with a liquid to form a suspension of the anion exchange resin, xanthan gum, and edible, water soluble salt.

Abstract: Method for the treatment of human and lower animals having an infectious gastrointestinal disorder, comprising the step of administering from about 50 to about 5000 milligrams of bismuth to said subject, per day, for from 3 to 56 days. Preferred processes also include a step for performing a diagnostic step on the subject for detection of campylobacter-like organism infection of the subject.

Abstract: This invention relates to an oral pharmaceutical composition comprising from about 1% to 75%, by weight, psyllium husk with more than about 97% of the psyllium husk being smaller than about 100 mesh screen; from about 1% to 65%, by weight, cholestyramine; and wherein the ratio of the psyllium husk to the cholestyramine is from about 3:1 to about 1:2, and wherein the composition delivers from 1 g to 30 g of the psyllium husk and from about 4 g to about 30 g of the cholestyramine daily when the composition is taken orally in one or more doses.

Abstract: The subject invention encompasses a transdermally or transmucosally administrable composition for the treatment or nicotine craving or smoking withdrawal symptoms comprising nicotine and caffeine or caffeine equivalent.